Inspira Technologies Validates Standalone HYLA System, Targets $50 Billion Heart-Lung Surgery Market

New updates have been reported about Inspira Technologies.

Inspira Technologies has validated its next-generation standalone HYLA blood monitoring system in its advanced blood laboratories, confirming 94.2% accuracy in continuous optical measurement of pCO₂ within a 7 mmHg threshold versus gold-standard blood gas analyzers. By decoupling HYLA from its own respiratory support hardware and configuring it as a standalone platform, the company positions the system for integration into existing operating room and ICU workflows, enabling use across the global installed base of heart-lung machines and ECMO systems and immediate access, upon regulatory clearance, to an estimated $50 billion heart-lung surgery market. The system provides continuous, non-invasive tracking of patients’ metabolic status, addressing clinical “blind spots” inherent in intermittent blood draws and potentially reducing complications during extracorporeal procedures.

Strategically, Inspira is pivoting HYLA into a universal, hardware-agnostic sensor platform that underpins a high-margin recurring revenue model built on disposable optical sensors and modular software upgrades, expanding the company’s total addressable market beyond its INSPIRA ART life-support systems. CEO Dagi Ben-Noon said the validation confirms the technology is operating at clinical grade and supports a faster market entry independent of the rollout of the ART system, with a U.S. FDA submission targeted for 2026. The standalone HYLA initiative aligns with Inspira’s broader roadmap in blood-based diagnostics, including its recently proposed potential acquisition of an advanced liquid biopsy business, and builds on the commercial foundation of its FDA-cleared INSPIRA ART100 cardiopulmonary bypass/ECMO platform and development of the next-generation ART500 system. For executives and investors, this move signals a shift toward a scalable platform strategy in medtech monitoring, with regulatory execution, adoption by perfusion and ICU stakeholders, and successful deployment of the recurring revenue model as key value drivers over the next several years.